Vestpro Financial Partners Inc. dba CPF Texas bought a new stake in Eli Lilly and Co (NYSE:LLY) in the 4th quarter, HoldingsChannel reports. The fund bought 2,400 shares of the company’s stock, valued at approximately $203,000.
Other hedge funds have also recently made changes to their positions in the company. Beach Investment Management LLC. acquired a new stake in Eli Lilly and in the second quarter valued at $400,000. Penserra Capital Management LLC raised its holdings in Eli Lilly and by 13.0% in the second quarter. Penserra Capital Management LLC now owns 2,288 shares of the company’s stock valued at $188,000 after acquiring an additional 264 shares in the last quarter. Canandaigua National Bank & Trust Co. raised its holdings in Eli Lilly and by 5.2% in the second quarter. Canandaigua National Bank & Trust Co. now owns 10,062 shares of the company’s stock valued at $828,000 after acquiring an additional 493 shares in the last quarter. Sfmg LLC raised its holdings in Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after acquiring an additional 20 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. raised its holdings in Eli Lilly and by 14.7% in the second quarter. Robeco Institutional Asset Management B.V. now owns 230,341 shares of the company’s stock valued at $18,959,000 after acquiring an additional 29,478 shares in the last quarter. Institutional investors and hedge funds own 76.20% of the company’s stock.
Several research firms recently issued reports on LLY. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, October 24th. Bank of America cut their price target on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, February 1st. Credit Suisse Group reaffirmed a “hold” rating and issued a $80.00 price target on shares of Eli Lilly and in a report on Friday, February 2nd. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a report on Thursday, October 26th. Finally, Leerink Swann upped their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $92.02.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.06. The company had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.95 earnings per share. sell-side analysts anticipate that Eli Lilly and Co will post 4.87 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.85%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is -1,124.94%.
In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the transaction, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. Insiders have sold 259,610 shares of company stock worth $22,727,406 over the last three months. 0.20% of the stock is owned by corporate insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.